dc.contributor.author | Düğeroğlu, Harun | |
dc.contributor.author | Öztürk, Mustafa | |
dc.contributor.author | Atmaca, Murat | |
dc.contributor.author | Seven, İsmet | |
dc.date.accessioned | 10.07.201910:49:13 | |
dc.date.accessioned | 2019-07-10T19:35:26Z | |
dc.date.available | 10.07.201910:49:14 | |
dc.date.available | 2019-07-10T19:35:26Z | |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Düğeroğlu, H., Öztürk, M., Atmaca, M. ve Seven, İ. (2014). Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms. Journal of the Pakistan Medical Association, 64(12), 1366-1369. | en_US |
dc.identifier.issn | 0030-9982 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/774 | |
dc.description.abstract | Objective: To investigate the effects of mesterolone on prostate in patients treated for aging male syndrome.Methods: The cross-sectional study was conducted from June to September, 2009, at endocrinology and metabolism department of Yuzuncu Yil University, Van, Turkey, and comprised patients with symptoms of aging male syndrome and/or low testosterone. They were given mesterolone 50mg/day per oral for two months. Aging Male Symptoms and International Prostate Symptom Score questionaires and prostate-related quality of life scores were completed and prostate ultrasonography (USG) was performed before and after the treatment. Total testosterone, free testosterone, gonadotropins, estradiol, prolactin, sex-hormone binding globulin, as well as total and free prostate-specific antigen were also studied.Results: Of the 34 patients in the study, 22(64.70%) had their prostate volume increased, while 12(35.29%) had it decreased. The change, however, was not statistically significant (p<0.098). Mesterolone significantly improved Aging Male Symptoms, International Prostate Symptom and prostate-related quality of life scores (p<0.001). These improvements though significant were independent of the changes in prostate volume. Total testosterone, sexhormone binding globulin andestradiol decreased, while free testosterone showed no change (p<0.002, p<0.001, p<0.024, p<0.337). The fraction of free testosterone increased (p<0.001), while total and free prostate-specific antigen did not change (p<0.368 and p<0.841).Conclusion: Mesterolone proved to be a safe alternative in the treatment of Aging Male Syndrome. It also improved lower urinary tract symptoms and prostate-related quality of life. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Pakistan Medical Association | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Andropause | en_US |
dc.subject | Mesterolone | en_US |
dc.subject | Prostate | en_US |
dc.title | Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of the Pakistan Medical Association | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-0947-9498 | en_US |
dc.identifier.volume | 64 | en_US |
dc.identifier.issue | 12 | en_US |
dc.identifier.startpage | 1366 | en_US |
dc.identifier.endpage | 1369 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.identifier.scopusquality | Q3 | en_US |